Transcutaneous Application of Gaseous CO2

Sponsor
University Medical Centre Ljubljana (Other)
Overall Status
Recruiting
CT.gov ID
NCT04561609
Collaborator
(none)
60
1
2
19.9
3

Study Details

Study Description

Brief Summary

The research is designed to evaluate influence of transcutaneous application of CO2 (carbon dioxide) on peripheral diabetic neuropathy. Transcutaneous application of CO2 is known to have immediate effect on vasodilatation and elevates oxygen release from Hb via the Bohr effect. After repetition of the therapies neoangiogenesis is induced. Impairment of microcirculation is one of the causes of diabetic peripheral neuropathy and improvement in circulation could have positive effect also on peripheral neuropathy. In order to evaluate the effect of transcutaneous application of CO2 on peripheral neuropathy in diabetic patients the investigators designed a randomised double blind clinical trial.

Condition or Disease Intervention/Treatment Phase
  • Other: Transcutaneous CO2 application
  • Other: Placebo treatment
N/A

Detailed Description

Transcutaneous application of gaseous CO2 showed to be a successful adjuvant therapy in treatment of chronic wounds in diabetic patients (PMID: 32633896). During that research patients reported improvement in peripheral sensation after treatment. Therefore, in order to investigate the influence of transcutaneous application of gaseous CO2 in peripheral diabetic neuropathy the investigators designed a randomised double blind research. 60 diabetic patients with peripheral diabetic neuropathy will be randomised in study and control group. Study group will receive 20 treatments with CO2 (each workday for 4 weeks). Lower part of the body is inserted into therapeutic wrap that is filled with 99.9% CO2 gas for 45 minutes. The same approach will be used in control group but in their case the therapeutic wrap will be filled with air. In both groups investigator will evaluate vibration sensation, monofilament test and temperature of the big toe before first and after 4 weeks of treatment. Patients as well as investigator (doctor) will be blind for the group belonging of the patients. The medical nurse performing all the therapies will randomise the patients using random number generator into study and control group. The nurse will be the only one knowing group belonging of the patients until the obtained results from both groups will be compared.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The use of transcutaneous application of gaseous CO2 for treatment of diabetic peripheral neuropathy. A double blind clinical trial. Control group receives placebo treatment.The use of transcutaneous application of gaseous CO2 for treatment of diabetic peripheral neuropathy. A double blind clinical trial. Control group receives placebo treatment.
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Masking Description:
Patients will not know to which group they belong. They will all receive treatment (study group with CO2, control group with air), the nurse who will prepare the gas for treatment will know the group belonging for the patient. The investigator, who will evaluate neuropathy before and after treatment will not know the group belonging of the patient. At the end, the person evaluating the results will compare results from 2 groups, not knowing which one was study and which control.
Primary Purpose:
Treatment
Official Title:
The Effect of Transcutaneous Application of Gaseous CO2 on Diabetic Symmetrical Peripheral Neuropathy - A Double Blind Randomized Clinical Trial
Actual Study Start Date :
May 2, 2020
Anticipated Primary Completion Date :
Sep 30, 2021
Anticipated Study Completion Date :
Dec 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: CO2 treated

Patients receiving treatment with transcutaneous application of gaseous CO2 on lower limbs

Other: Transcutaneous CO2 application
Patients lie on examination tables. Lower extremities of the patients are isolated in a therapeutic wrap (single use, low-density, made from biocompatible polyethylene), sealed at the waist. After this, air is first pumped out of the therapeutic wrap, then the wrap was filled with 99.9% CO2 gas. The therapy lasts for 45 minutes. Each patient from the study group will receive CO2 therapies - four weeks (meaning 20 CO2 therapies that were performed on workdays only).

Placebo Comparator: control

Patients receiving placebo treatment with air on lower limbs

Other: Placebo treatment
Each patient from control group will have therapeutic wrap filled with air instead of CO2. Patients from control group will also receive 20 therapies (4 weeks on workdays only), that will also last 45 minutes.

Outcome Measures

Primary Outcome Measures

  1. Change in Vibration sensation [before first therapy with CO2 or placebo and after 4 weeks of therapy with CO2 or placebo]

    Vibration sensation is performed using a 128 Hz tuning fork on 5 standard points on each foot (on the skin above a bony prominence the first metatarsophalangeal joint (MPT), the apex of the hallux, malleolus, diaphysis of tibia and tibia tuberosity). Results are presented as number of points (out of 10) with no vibration sensation.

  2. Change in Monofilament test [before first therapy with CO2 or placebo and after 4 weeks of therapy with CO2 or placebo]

    Monofilament testing is performed using Semmes Weinstein Monofilament (SWM) 10 g on 8 standard points on each foot (on the plantar surface of the great toe, third and fifth toe, on the plantar surface of the first, third and fifth metatarsal head, on the plantar arch and on the plantar surface of the calcaneus). Results are presented as number of points (out of 16) with no sensation.

Secondary Outcome Measures

  1. Change in skin temperature [before first therapy with CO2 or placebo and after 4 weeks of therapy with CO2 or placebo]

    the temperature measured with infrared thermometer on the plantar of the big toes using infrared thermometer. Temperature measurement was standardized - before treatment (in order to exclude increased temperature during the CO2 therapy due to vasodilatation). Patients are left to lie on the examination table, barefoot for 20 minutes to adjust to the room temperature.

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients with diabetes and peripheral symmetrical diabetic neuropathy

  • with unilateral chronic wound, without previous amputations

  • with scores above 3 on the Michigan Neuropathy Scoring Instrument

Exclusion Criteria:
  • diabetic patients with asymmetrical peripheral neuropathy

  • patients with severe comorbidities: deep vein thrombosis, chronic kidney diseases grade III and IV, chronic heart diseases NYHA (New York Heart Association) III and IV, patients with known malignant diseases, patients with progressive infection, signs of systemic infection with elevated inflammatory markers or osteomyelitis

Contacts and Locations

Locations

Site City State Country Postal Code
1 UMCLjubljana Ljubljana Slovenia 1000

Sponsors and Collaborators

  • University Medical Centre Ljubljana

Investigators

  • Principal Investigator: Igor Frangez, PhD, MD, DDS, UCMLjubljana

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Helena Ban Frangez, assistant professor MD, PhD, University Medical Centre Ljubljana
ClinicalTrials.gov Identifier:
NCT04561609
Other Study ID Numbers:
  • UMCLjubljana CO2 application
First Posted:
Sep 23, 2020
Last Update Posted:
Nov 3, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Helena Ban Frangez, assistant professor MD, PhD, University Medical Centre Ljubljana
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 3, 2020